- Report
- April 2025
- 175 Pages
Global
From €4029EUR$4,490USD£3,467GBP
- Report
- March 2025
- 175 Pages
Global
From €4029EUR$4,490USD£3,467GBP
- Report
- March 2025
- 250 Pages
Global
From €4029EUR$4,490USD£3,467GBP
- Report
- February 2025
- 200 Pages
Global
From €4029EUR$4,490USD£3,467GBP
- Report
- May 2024
- 129 Pages
Global
From €5831EUR$6,499USD£5,019GBP
- Drug Pipelines
- March 2025
- 450 Pages
Global
From €4486EUR$5,000USD£3,861GBP
- Clinical Trials
- March 2025
- 60 Pages
Global
From €1346EUR$1,500USD£1,158GBP
- Drug Pipelines
- March 2025
- 280 Pages
Global
From €2692EUR$3,000USD£2,317GBP
- Report
- February 2025
- 233 Pages
Global
From €2243EUR$2,500USD£1,931GBP
- Report
- July 2024
- 110 Pages
Global
From €4262EUR$4,750USD£3,668GBP
- Report
- January 2025
- 120 Pages
Global
€4990EUR$5,957USD£4,445GBP
- Report
- May 2023
- 391 Pages
Global
From €4306EUR$4,799USD£3,706GBP
- Report
- August 2023
- 267 Pages
Global
From €2150EUR$2,567USD£1,915GBP
- Report
- August 2023
- 175 Pages
Global
From €5339EUR$5,950USD£4,595GBP
- Drug Pipelines
- July 2020
- 33 Pages
Global
From €3140EUR$3,500USD£2,703GBP
- Clinical Trials
- January 2024
- 120 Pages
Global
From €2692EUR$3,000USD£2,317GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €2692EUR$3,000USD£2,317GBP
- Clinical Trials
- April 2024
- 550 Pages
Global
From €4486EUR$5,000USD£3,861GBP
- Drug Pipelines
- April 2024
- 80 Pages
Global
From €1795EUR$2,000USD£1,545GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1795EUR$2,000USD£1,545GBP

The Cluster of Differentiation 3 (CD3) market is a subset of the oncology drug market that focuses on drugs that target the CD3 molecule. CD3 is a protein found on the surface of T-cells, which are a type of white blood cell that plays a key role in the body's immune system. CD3-targeting drugs are used to treat a variety of cancers, including leukemia, lymphoma, and multiple myeloma. These drugs work by blocking the CD3 molecule, which prevents the T-cells from attacking healthy cells and helps to reduce the growth of cancer cells.
Some of the companies in the CD3 market include Novartis, Merck, Pfizer, and Bristol-Myers Squibb. These companies have developed a range of CD3-targeting drugs, including Imbruvica, Keytruda, and Opdivo. These drugs have been approved by the FDA for the treatment of various types of cancer and are widely used in the oncology field. Show Less Read more